GlassScriptPhysician profile
Sara Khan
NPI 1578020079
$3,822.72
in general payments reported to CMS, 2019-2025
31 companies · $37.27 in 2025
The $37.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,202 · 2022: $723 · 2023: $647 · 2024: $213 · 2025: $37.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $760.38 | 2021 | |
| Lilly USA, LLC | $580.73 | 2021-2023 | Emgality, Amyvid |
| Abbvie INC. | $306.48 | 2021-2025 | |
| Ucb, INC. | $249.65 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $211.76 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $201.41 | 2021 | |
| Argenx US, INC. | $185.62 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Greenwich Biosciences, INC. | $169.22 | 2021 | |
| Amgen INC. | $140.37 | 2021 | |
| Pfizer INC. | $108.07 | 2023-2025 | |
| Sk Life Science, INC. | $104.79 | 2021-2023 | Xcopri |
| Avanir Pharmaceuticals, INC. | $90.64 | 2021-2022 | |
| Banner Life Sciences, LLC | $60.53 | 2023 | |
| Janssen Pharmaceuticals, INC | $59.76 | 2022-2023 | Ponvory |
| Horizon Therapeutics Plc | $57.13 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $53.11 | 2022-2023 | Vyepti |
| Almatica Pharma LLC | $51.06 | 2021-2023 | Gralise |
| Eisai INC. | $50.79 | 2021-2023 | |
| Biogen, INC. | $49.30 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $44.28 | 2022 | |
| Sunovion Pharmaceuticals INC. | $42.27 | 2021 | |
| Jazz Pharmaceuticals INC. | $40.00 | 2023 | |
| Supernus Pharmaceuticals, INC. | $36.10 | 2022 | |
| Neurocrine Biosciences, INC. | $32.29 | 2023 | Ongentys, Ingrezza |
| Acadia Pharmaceuticals INC | $24.57 | 2022 | |
| Genzyme Corporation | $23.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.60 | 2023 | Nuedexta |
| Scilex Pharmaceuticals INC. | $17.75 | 2023 | Ztlido |
| Celgene Corporation | $17.60 | 2022 | |
| Kyowa Kirin, INC. | $16.90 | 2023 | Nourianz |
| Currax Pharmaceuticals LLC | $15.03 | 2023 | Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.